Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy: a DBCG study.

Lyng MB, Lænkholm AV, Søkilde R, Gravgaard KH, Litman T, Ditzel HJ.

PLoS One. 2012;7(5):e36170. doi: 10.1371/journal.pone.0036170. Epub 2012 May 18.

2.

Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment.

Hoppe R, Achinger-Kawecka J, Winter S, Fritz P, Lo WY, Schroth W, Brauch H.

Eur J Cancer. 2013 Nov;49(17):3598-608. doi: 10.1016/j.ejca.2013.07.145. Epub 2013 Aug 19.

PMID:
23968733
3.

MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer.

Rodríguez-González FG, Sieuwerts AM, Smid M, Look MP, Meijer-van Gelder ME, de Weerd V, Sleijfer S, Martens JW, Foekens JA.

Breast Cancer Res Treat. 2011 May;127(1):43-51. doi: 10.1007/s10549-010-0940-x. Epub 2010 May 19.

PMID:
20490652
4.

Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment.

Yu KD, Di GH, Wu J, Lu JS, Shen KW, Liu GY, Shen ZZ, Shao ZM.

J Cancer Res Clin Oncol. 2008 Dec;134(12):1347-54. doi: 10.1007/s00432-008-0414-2. Epub 2008 May 17.

PMID:
18488249
5.

MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.

Ward A, Shukla K, Balwierz A, Soons Z, König R, Sahin O, Wiemann S.

J Pathol. 2014 Aug;233(4):368-79. doi: 10.1002/path.4363. Epub 2014 Jun 2.

6.

Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy.

Bartlett JM, Thomas J, Ross DT, Seitz RS, Ring BZ, Beck RA, Pedersen HC, Munro A, Kunkler IH, Campbell FM, Jack W, Kerr GR, Johnstone L, Cameron DA, Chetty U.

Breast Cancer Res. 2010;12(4):R47. doi: 10.1186/bcr2604. Epub 2010 Jul 8.

7.

Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.

Kennecke H, McArthur H, Olivotto IA, Speers C, Bajdik C, Chia SK, Ellard S, Norris B, Hayes M, Barnett J, Gelmon KA.

Cancer. 2008 Apr 1;112(7):1437-44. doi: 10.1002/cncr.23320.

8.

An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.

Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlertsen B, Mouridsen HT.

Acta Oncol. 2009;48(4):522-31. doi: 10.1080/02841860802676383.

PMID:
19173092
9.

A novel MAPK-microRNA signature is predictive of hormone-therapy resistance and poor outcome in ER-positive breast cancer.

Miller PC, Clarke J, Koru-Sengul T, Brinkman J, El-Ashry D.

Clin Cancer Res. 2015 Jan 15;21(2):373-85. doi: 10.1158/1078-0432.CCR-14-2053. Epub 2014 Nov 4.

10.

A candidate molecular signature associated with tamoxifen failure in primary breast cancer.

Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.

Breast Cancer Res. 2008;10(5):R88. doi: 10.1186/bcr2158. Epub 2008 Oct 17.

11.

A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.

Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, Pho M, Baker J, Walker M, Watson D, Hackett J, Blick NT, Greenberg D, Fehrenbacher L, Langholz B, Quesenberry CP.

Breast Cancer Res. 2006;8(3):R25. Epub 2006 May 31.

12.

Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.

Linderholm B, Bergqvist J, Hellborg H, Johansson U, Linderholm M, von Schoultz E, Elmberger G, Skoog L, Bergh J.

Med Oncol. 2009 Dec;26(4):480-90. doi: 10.1007/s12032-008-9157-9. Epub 2009 Jan 7.

PMID:
19130322
13.

Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer.

Rothé F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, Majjaj S, Badran B, Fayyad-Kazan H, Desmedt C, Harris AL, Piccart M, Sotiriou C.

PLoS One. 2011;6(6):e20980. doi: 10.1371/journal.pone.0020980. Epub 2011 Jun 29.

14.

A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer.

Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, Mac Grogan G, Mauriac L, Katsaros D, Molina F, Theillet C, Darbon JM.

Clin Cancer Res. 2008 Mar 15;14(6):1744-52. doi: 10.1158/1078-0432.CCR-07-1833.

15.

Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer.

Han W, Han MR, Kang JJ, Bae JY, Lee JH, Bae YJ, Lee JE, Shin HJ, Hwang KT, Hwang SE, Kim SW, Noh DY.

BMC Cancer. 2006 Apr 12;6:92.

16.

Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.

Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J, Cronin M, Walker M, Watson D, Shak S, Hortobagyi GN.

Clin Cancer Res. 2005 May 1;11(9):3315-9.

17.

Factors predictive of response to hormone therapy in breast cancer.

Rastelli F, Crispino S.

Tumori. 2008 May-Jun;94(3):370-83. Review.

18.

Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group.

Fernö M, Stål O, Baldetorp B, Hatschek T, Källström AC, Malmström P, Nordenskjöld B, Rydën S.

Breast Cancer Res Treat. 2000 Jan;59(1):69-76.

PMID:
10752681
19.

Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer.

Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, Lavaill R, Mollevi C, Warner M, Gustafsson JA, Rochefort H.

Clin Cancer Res. 2004 Sep 1;10(17):5769-76.

20.

Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen.

Khoshnoud MR, Löfdahl B, Fohlin H, Fornander T, Stål O, Skoog L, Bergh J, Nordenskjöld B.

Breast Cancer Res Treat. 2011 Apr;126(2):421-30. doi: 10.1007/s10549-010-1202-7. Epub 2010 Oct 19.

PMID:
20957430

Supplemental Content

Support Center